Feasibility and clinical benefits of the double-ProGlide technique for hemostasis after cryoballoon atrial fibrillation ablation with uninterrupted oral anticoagulants

OBJECTIVE To access the efficacy and safety of the double-ProGlide technique for the femoral vein access-site closure in cryoballoon ablation with uninterrupted oral anticoagulants(OAC),and its impact on the electrophysiology laboratory time as well as hospital stay after the procedure in this observational study.METHODS Patients with atrial fibrillation undergoing cryoballoon ablation with uninterrupted OAC at Department of Cardiology,Beijing Anzhen Hospital,Capital Medical University,Beijing,China from May 2019 to May 2021 were enrolled in this study.From October 2020,double-ProGlide technique was consistently used for hemostasis(ProGlide group),and before that conventional manual compression was utilized(manual compression group).The occurrence of vascular and groin complications was accessed during the hospital stay and until the three-month follow-up.RESULTS A total of 140 participants(69.30%of male,mean age:59.21±10.29 years)were evaluated,70 participants being in each group.Immediate hemostasis was achieved in all the patients with ProGlide closure.No major vascular complications were found in the ProGlide group while two major vascular complications were occurred in the manual compression group.The incidence of any groin complication was obviously higher in subjects with manual compression than patients with ProGlide devices(15.71%vs.2.86%,P=0.009).In addition,compared with the manual compression group,the ProGlide group was associated with significantly shorter total time in the electrophysiology laboratory[112.0(93.3–128.8)min vs.123.5(107.3–158.3)min,P=0.006],time from sheath removal until venous site hemostasis[3.8(3.4–4.2)min vs.8.0(7.6–8.5)min,P<0.001],bed rest time[8.0(7.6–8.0)h vs.14.1(12.0–17.6)h,P<0.001]and hospital stay after the procedure[13.8(12.5–17.8)h vs.38.0(21.5–41.0)h,P<0.001].CONCLUSIONS Utilization of the double-ProGlide technique for hemostasis after cryoballoon ablation with uninterrupted OAC is feasible and safe,which has the clinical benefit in reducing the total electrophysiology laboratory time and the hospital stay length after the procedure.

ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer

Objective Cisplatin(CDDP)-based chemotherapy is a first-line,drug regimen for muscle-invasive bladder cancer(BC)and metastatic bladder cancer.Clinically,resistance to CDDP restricts the clinical benefit of some bladder cancer patients.AT-rich interaction domain 1A(ARID1A)gene mutation occurs frequently in bladder cancer;however,the role of CDDP sensitivity in BC has not been studied.Methods We established ARID1A knockout BC cell lines using CRISPR/Cas9 technology.IC50 determination,flow cytometry analysis of apoptosis,and tumor xenograft assays were performed to verify changes in the CDDP sensitivity of BC cells losing ARID1A.qRT-PCR,Western blotting,RNA interference,bioinformatic analysis,and ChIP-qPCR analysis were performed to further explore the potential mechanism of ARID1A inactivation in CDDP sensitivity in BC.Results It was found that ARID1A inactivation was associated with CDDP resistance in BC cells.Mechanically,loss of ARID1A promoted the expression of eukaryotic translation initiation factor 4A3(EIF4A3)through epigenetic regulation.Increased expression of EIF4A3 promoted the expression of hsa_circ_0008399(circ0008399),a novel circular RNA(circRNA)identified in our previous study,which,to some extent,showed that ARID1A deletion caused CDDP resistance through the inhibitory effect of circ0008399 on the apoptosis of BC cells.Importantly,EIF4A3-IN-2 specifically inhibited the activity of EIF4A3 to reduce circ0008399 production and restored the sensitivity of ARID1A inactivated BC cells to CDDP.Conclusion Our research deepens the understanding of the mechanisms of CDDP resistance in BC and elucidates a potential strategy to improve the efficacy of CDDP in BC patients with ARID1A deletion through combination therapy targeting EIF4A3.

Erratum to:ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer

The original version of this article was revised due to production error by the vendor.The author“Hua-min DING”is one of the co-authors,and the name should be labeled correctly as appears on PDF.The affiliation of“Yu-jun SHUAI”and“Chao HUANG”is“Department of Urology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China”,and both of them should be labeled as 1,as correctively appears on PDF.

Efficacy and Safety of COX-2 Inhibitor Parecoxib for Rigid Cystoscopyrelated Pain Management in Male Patients:A Prospective,Randomized and Controlled Study

Using anesthetic gel may not sufficiently exclude pain perception during and after cystoscopy in male patients.To evaluate the analgesic efficacy and safety of intramuscular parecoxib(40 mg)for outpatient-based rigid cystoscopy,we performed a prospective,randomized and controlled study.Consecutive male patients requiring diagnostic cystoscopy in our hospital were divided into group A(1%tetracaine gel,n=50)and group B(parecoxib,n^5l)at random.Patients received intramuscular injections of either 2 mL sterile saline in group A or 40 mg parecoxib in group B 30 min before the procedure.Tetracaine gel was injected into the urethra 3 min before the procedure in group A,with patients receiving plain lubricant gel in group B at the same time.Cystoscopy-associated pain levels were evaluated using the Visual Analog Score(VAS)during the procedure.Post-procedure urethral pain and complications were recorded and analyzed.The results showed that male patients experienced significantly less pain in group B than in group A(2.70±1.36 V5.3.56±1.74,P=0.008).The percentage of patients with dysuria pain was not significantly different between the two groups.In addition,24 h after cystoscopy,the patients with no previous experience of cystoscopy were more likely to declare urethral pain(59.2%vs.33.3%,P=0.012,relative risk=1.78).No difference was observed in analgesic-related complications between the two groups.We conclude that intramuscular injection of 40 mg parecoxib may improve comfort for male patients undergoing rigid cystoscopy.

Rapid chemical recycling of waste polyester plastics catalyzed by recyclable catalyst

Waste plastics are serious environmental threats due to their low degradability and low recycling rate.Rapid and efficient waste plastics recycling technologies are urgently demanded for a sustainable future.Herein,we report a rapid,closed-loop,and streamlined process to convert polyesters such as poly(ethylene terephthalate)(PET)back to its purified monomers.Using trifluoromethanesulfonic acid or metal triflates as the recyclable catalyst,polyesters such as PET can be completely depolymerized by simple carboxylic acids within 1 h.By coupling this acidolysis with a subsequent hydrogenolysis process,the consumed carboxylic acid was recovered and the closed-loop of PET depolymerization could be established.All catalysts and depolymerization agents are fully recycled while only PET and hydrogen are consumed.